Long-acting basal insulin analogs: Latest developments and clinical usefulness

Therapeutic Advances in Chronic Disease

Volumn 3, Issue 6, 2012, Pages 249-257

  Mavrogiannaki, Anastasia N ^a   Migdalis, Ilias N ^a  

^a NIMTS Hospital   (United States)

Author keywords

Basal insulin analogs; Cancer; Clinical effectiveness; Diabetes mellitus; Hypoglycemia

Indexed keywords

BASAL INSULIN DERIVATIVE; GLIMEPIRIDE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN DEGLUDEC; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; INSULIN PEGLISPRO; ISOPHANE INSULIN; LY 2963016; ORAL ANTIDIABETIC AGENT; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; BEDTIME DOSAGE; BODY WEIGHT; CANCER RISK; CHILD HEALTH CARE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG ABSORPTION; DRUG SCREENING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS (TOPIC); MORNING DOSAGE; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SIDE EFFECT; WEIGHT GAIN;

EID: 84875537958     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622312454158     Document Type: Review

References (50)

1. Arutchelvam V. Heise T. Dellweg S. Elbroend B. Minns I. Home P. (2009) Plasma glucose and hypoglycaemia following exercise in people with type 1 diabetes: a comparison of three basal insulins. Diabet Med 26: 1027–1032.
2. Bush M. (2007) Intensive diabetes therapy and body weight: focus on insulin detemir. Endocrinol Metab Clin North Am 36(Suppl 1): 33–44.
3. Cameron C. Bennett H. (2009) Cost-effectiveness of insulin analogues for diabetes mellitus. CMAJ 180: 400–407.
4. Chase H. Dixon B. Pearson J. Fiallo-Scharer R. Walravens P. Klingensmith G. et al. (2003) Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin. J Pediatr 143: 737–740.
5. Ciaraldi T. Carter L. Seipke G. Mudaliar S. Henry R. (2001) Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I. J Clin Endocrinol Metab 86: 5838–5847.
6. Colhoun H. ; SDRN Epidemiology Group. (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52: 1755–1765.
7. Currie C. Poole C. Gale E. (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52: 1766–1777.
8. Dailey G. Admane K. Mercier F. Owens D. (2010) Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir. Diabetes Technol Ther 12: 1019–1027.
9. Dejgaard A. Lynggaard H. Råstam J. Krogsgaard Thomsen M. (2009) No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia 52: 2507–2512.
10. Dornhorst A. Lüddeke H. Koenen C. Meriläinen M. King A. Robinson A. et al. (2008) Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE. Diabetes Obes Metab 10: 75–81.
11. Esposito K. Giugliano D. (2012) Current insulin analogues in the treatment of diabetes: emphasis on type 2 diabetes. Expert Opin Biol Ther 12: 209–221.
12. Fogelfeld L. Dharmalingam M. Robling K. Jones C. Swanson D. Jacober S. (2010) A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naïve patients with type 2 diabetes. Diabet Med 27: 181–188.
13. Fritsche A. Schweitzer M. Häring H. ; 4001 Study Group. (2003) Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 138: 952–959.
14. Garg S. Moser E. Dain M. Rodionova A. (2010) Clinical experience with insulin glargine in type 1 diabetes. Diabetes Technol Ther 12: 835–846.
15. Giovannucci E. Harlan D. Archer M. Bergenstal R. Gapstur S. Habel L. et al. (2010) Diabetes and cancer: a consensus report. Diabetes Care 33: 1674–1685.
16. Giugliano D. Maiorino M. Bellastella G. Chiodini P. Ceriello A. Esposito K. (2011) Efficacy of insulin analogs in achieving the hemoglobin A1c target of < 7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care 34: 510–517.
17. Gough S. (2007) A review of human and analogue insulin trials. Diabetes Res Clin Pract 77: 1–15.
18. Haak T. Tiengo A. Draeger E. Suntum M. Waldhäusl W. (2005) Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 7: 56–64.
19. Hallschmid M. Jauch-Chara K. Korn O. Mölle M. Rasch B. Born J. et al. (2010) Euglycemic infusion of insulin detemir compared with human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects. Diabetes 59: 1101–1107.
20. Hamann A. Matthaei S. Rosak C. Silvestre L. ; HOE901/4007 Study Group. (2003) A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care 26: 1738–1744.
21. Heinemann L. Linkeschova R. Rave K. Hompesch B. Sedlak M. Heise T. (2000) Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23: 644–649.
22. Hemkens L. Grouven U. Bender R. Günster C. Gutschmidt S. Selke G. et al. (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52: 1732–1744.
23. Hermansen K. Davies M. (2007) Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab 9: 209–217.
24. Home P. Lagarenne P. (2009) Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 52: 2499–2506.
25. Hompesch M. Ocheltree S. Wondmagegnehu E. Morrow L. Kollmeier A. Campaigne B. et al. (2009) Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. Curr Med Res Opin 25: 2679–2687.
26. Jensen M. Hansen M. Brock B. Rungby J. (2010) Differences between long-acting insulins for the treatment of type 2 diabetes. Expert Opin Pharmacother 11: 2027–2035.
27. Jonasson J. Ljung R. Talbäck M. Haglund B. Gudbjörnsdòttir S. Steineck G. (2009) Insulin glargine use and short-term incidence of malignancies – a population-based follow-up study in Sweden. Diabetologia 52: 1745–1754.
28. Koivisto V. Cleall S. Pontiroli A. Giugliano D. (2011) Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial. Diabetes Obes Metab 13: 1149–1157.
29. Kurtzhals P. Schäffer L. Sørensen A. Kristensen C. Jonassen I. Schmid C. et al. (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49: 999–1005.
30. Lindsay R. Ziegler A. Hamilton B. Calder A. Johnstone F. Walker J. (2004) Type 1 diabetes-related antibodies in the fetal circulation: prevalence and influence on cord insulin and birth weight in offspring of mothers with type 1 diabetes. J Clin Endocrinol 89: 3436–3439.
31. Meneghini L. Bresta M. (2012) Insulin degludec: a novel ultra-long-acting basal insulin for use in type 1 and 2 diabetes. Expert Rev Endocrinol Metab 7: 9–14.
32. Migdalis I. (2011) Insulin analogs versus human insulin in type 2 diabetes. Diabetes Res Clin Pract 93(Suppl 1): S102–S104.
33. Mohn A. Strang S. Wernicke-Panten K. Lang A. Edge J. Dunger D. (2000) Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen. Diabetes Care 23: 557–559.
34. Negrato C. Rafacho A. Negrato G. Teixeira M. Araújo C. Vieira L. et al. (2010) Glargine versus NPH insulin therapy in pregnancies complicated by diabetes: an observational cohort study. Diabetes Res Clin Pract 89: 46–51.
35. Niswender K. (2011) Basal insulin: physiology, pharmacology, and clinical implications. Postgrad Med 123: 17–26.
36. Pickup J. Sutton A. (2008) Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 25: 765–774.
37. Pieber T. Treichel H. Hompesch B. Philotheou A. Mordhorst L. Gall M. et al. (2007) Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy. Diabet Med 24: 635–642.
38. Pontiroli A. Miele L. Morabito A. (2011) Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab 13: 1008–1019.
39. Poon K. King A. (2010) Glargine and detemir: safety and efficacy profiles of the long-acting basal insulin analogs. Drug Health Patient Saf 2: 213–223.
40. Porcellati F. Bolli G. Fanelli C. (2011) Pharmacokinetics and pharmacodynamics of basal insulins. Diabetes Technol Ther 13(Suppl 1): S15–S24.
41. Rhoads G. Kosiborod M. Nesto R. Fonseca V. Lu S. Zhang Q. et al. (2009) Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine. Am J Cardiol 104: 910–916.
42. Rosenstock J. Dailey G. Massi-Benedetti M. Fritsche A. Lin Z. Salzman A. (2005) Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 28: 950–955.
43. Rosenstock J. Fonseca V. McGill J. Riddle M. Hallé J. Hramiak I. et al. (2009) Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia 52: 1971–1973.
44. Singh S. Ahmad F. Lal A. Yu C. Bai Z. Bennett H. (2009) Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 180: 385–397.
45. Sommerfeld M. Müller G. Tschank G. Seipke G. Habermann P. Kurrle R. et al. (2010) In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PloS ONE 5: e9540.
46. Swinnen S. Dain M. Aronson R. Davies M. Gerstein H. Pfeiffer A. et al. (2010) A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care 33: 1176–1178.
47. Swinnen S. Simon A. Holleman F. Hoekstra J. Devries J. (2011) Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev 7: CD006383.
48. Torlone E. Di Cianni G. Mannino D. Lapolla A. (2009) Insulin analogs and pregnancy: an update. Acta Diabetol 46: 163–172.
49. Werner H. Weinstein D. Yehezkel E. Laron Z. (2011) Controversies in the use of insulin analogues. Expert Opin Biol Ther 11: 199–209.
50. Zib I. Raskin P. (2006) Novel insulin analogues and its mitogenic potential. Diabetes Obes Metab 8: 611–620.